PDF(Pubmed)
Abstract：
UNASSIGNED: To comprehensively evaluate the effectiveness and safety of lorecivivint inhibitors in the treatment of osteoarthritis through meta-analysis.
UNASSIGNED: A comprehensive literature search on lorecivivint inhibitors in osteoarthritis was performed using electronic databases such as PubMed, Embase, Web of Science, and CochraneLibrary up to July 30, 2022. Two reviewers independently screened, evaluated, and reviewed the eligible studies. Data analysis and processing were carried out using RevMan 5.4 software.
UNASSIGNED: A total of six studies involving 3056 participants were included. Meta-analysis showed that compared with the control group, lorecivivint significantly increased WOMAC discomfort (0.03 mg Week 12) (MD = -0.21, 95% CI [-1.94 - 1.53]; P = 0.81), WOMAC function (0.07 mg Week 24) (MD = -1.81, 95% CI [-4.74 - 1.12]; P = 0.23) and Joint space width (0.23 mg Week 24) (MD = -1.16, 95% CI [-3.69 - 1.38]; P = 0.37).
UNASSIGNED: A new treatment method combining Wnt pathway modulators with intra-articular CLK2/DYRK1A inhibitors could be a promising therapy for treating osteoarthritis. Lorecivivint was found to significantly improve WOMAC discomfort, WOMAC function, and joint space width in osteoarthritis patients. It is anticipated to be a reliable, safe, and effective treatment option for osteoarthritis with significant therapeutic utility and potential applications.
UNASSIGNED: A comprehensive literature search on lorecivivint inhibitors in osteoarthritis was performed using electronic databases such as PubMed, Embase, Web of Science, and CochraneLibrary up to July 30, 2022. Two reviewers independently screened, evaluated, and reviewed the eligible studies. Data analysis and processing were carried out using RevMan 5.4 software.
UNASSIGNED: A total of six studies involving 3056 participants were included. Meta-analysis showed that compared with the control group, lorecivivint significantly increased WOMAC discomfort (0.03 mg Week 12) (MD = -0.21, 95% CI [-1.94 - 1.53]; P = 0.81), WOMAC function (0.07 mg Week 24) (MD = -1.81, 95% CI [-4.74 - 1.12]; P = 0.23) and Joint space width (0.23 mg Week 24) (MD = -1.16, 95% CI [-3.69 - 1.38]; P = 0.37).
UNASSIGNED: A new treatment method combining Wnt pathway modulators with intra-articular CLK2/DYRK1A inhibitors could be a promising therapy for treating osteoarthritis. Lorecivivint was found to significantly improve WOMAC discomfort, WOMAC function, and joint space width in osteoarthritis patients. It is anticipated to be a reliable, safe, and effective treatment option for osteoarthritis with significant therapeutic utility and potential applications.
摘要：
■通过荟萃分析全面评估lorecivint抑制剂治疗骨关节炎的有效性和安全性。
■使用电子数据库，如PubMed，Embase,WebofScience,和CochraneLibrary截至2022年7月30日。两名审稿人独立筛选，评估，并审查了符合条件的研究。采用RevMan5.4软件进行数据分析和处理。
■共纳入6项研究，涉及3056名参与者。Meta分析结果显示,与对照组相比,lorecivint显着增加WOMAC不适（0.03mg，第12周）（MD=-0.21，95％CI[-1.94-1.53]；P=0.81），WOMAC功能（0.07mg，第24周）（MD=-1.81，95％CI[-4.74-1.12]；P=0.23）和关节间隙宽度（0.23mg，第24周）（MD=-1.16，95％CI[-3.69-1.38]；P=0.37）。
■一种将Wnt通路调节剂与关节内CLK2/DYRK1A抑制剂结合的新治疗方法可能是治疗骨关节炎的有希望的疗法。Lorecivint被发现可以显着改善WOMAC的不适感，WOMAC功能,骨关节炎患者的关节间隙宽度。它预计是一个可靠的，安全,和骨关节炎的有效治疗选择，具有显著的治疗效用和潜在的应用。
■使用电子数据库，如PubMed，Embase,WebofScience,和CochraneLibrary截至2022年7月30日。两名审稿人独立筛选，评估，并审查了符合条件的研究。采用RevMan5.4软件进行数据分析和处理。
■共纳入6项研究，涉及3056名参与者。Meta分析结果显示,与对照组相比,lorecivint显着增加WOMAC不适（0.03mg，第12周）（MD=-0.21，95％CI[-1.94-1.53]；P=0.81），WOMAC功能（0.07mg，第24周）（MD=-1.81，95％CI[-4.74-1.12]；P=0.23）和关节间隙宽度（0.23mg，第24周）（MD=-1.16，95％CI[-3.69-1.38]；P=0.37）。
■一种将Wnt通路调节剂与关节内CLK2/DYRK1A抑制剂结合的新治疗方法可能是治疗骨关节炎的有希望的疗法。Lorecivint被发现可以显着改善WOMAC的不适感，WOMAC功能,骨关节炎患者的关节间隙宽度。它预计是一个可靠的，安全,和骨关节炎的有效治疗选择，具有显著的治疗效用和潜在的应用。
